Osteotropic Peptide that differentiates functional domains of the skeleton
- PMID: 17705416
- DOI: 10.1021/bc7002132
Osteotropic Peptide that differentiates functional domains of the skeleton
Abstract
HPMA copolymer-d-aspartic acid octapeptide (D-Asp8) conjugates have been found to target the entire skeleton after systemic administration. In a recent study using the ovariectomized rat model of osteoporosis, we surprisingly discovered that D-Asp8 would favorably recognize resorption sites in skeletal tissues, while another bone-targeting moiety, alendronate (ALN), directs the delivery system to both formation and resorption sites. Atomic force microscopy (AFM) analyses reveal that ALN has a stronger binding force to hydroxyapatite (HA) than D-Asp8. In vitro HA binding studies indicate that D-Asp8 is more sensitive to change of HA crystallinity than ALN. Because the bone apatite in the newly formed bone (formation sites) usually has lower crystallinity than the resorption sites (mainly mature bone), we believe that the favorable recognition of D-Asp8 to the bone resorption sites could be attributed to its relatively weak binding to apatite, when compared to bisphosphonates, and the different levels of crystallinity of bone apatite at different functional domains of the skeleton.
Similar articles
-
Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.Anat Rec (Hoboken). 2007 Aug;290(8):1005-16. doi: 10.1002/ar.20561. Anat Rec (Hoboken). 2007. PMID: 17610276
-
Onion decreases the ovariectomy-induced osteopenia in young adult rats.Bone. 2008 Jun;42(6):1154-63. doi: 10.1016/j.bone.2008.01.032. Epub 2008 Feb 29. Bone. 2008. PMID: 18387868
-
Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers.Mol Pharm. 2006 Nov-Dec;3(6):717-25. doi: 10.1021/mp0600539. Mol Pharm. 2006. PMID: 17140259 Free PMC article.
-
[New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].Clin Calcium. 2009 Jan;19(1):63-73. Clin Calcium. 2009. PMID: 19122266 Review. Japanese.
-
Cathepsin K inhibitors: a novel target for osteoporosis therapy.Clin Pharmacol Ther. 2008 Jan;83(1):172-6. doi: 10.1038/sj.clpt.6100450. Epub 2007 Dec 12. Clin Pharmacol Ther. 2008. PMID: 18073778 Review.
Cited by
-
Mineralized nanofiber segments coupled with calcium-binding BMP-2 peptides for alveolar bone regeneration.Acta Biomater. 2019 Feb;85:282-293. doi: 10.1016/j.actbio.2018.12.051. Epub 2018 Dec 31. Acta Biomater. 2019. PMID: 30605770 Free PMC article.
-
Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers.PLoS One. 2013 Dec 31;8(12):e84335. doi: 10.1371/journal.pone.0084335. eCollection 2013. PLoS One. 2013. PMID: 24391942 Free PMC article.
-
Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone.Bioconjug Chem. 2011 Dec 21;22(12):2496-506. doi: 10.1021/bc2003132. Epub 2011 Dec 5. Bioconjug Chem. 2011. PMID: 22073906 Free PMC article.
-
Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis?Int J Mol Sci. 2021 Aug 19;22(16):8932. doi: 10.3390/ijms22168932. Int J Mol Sci. 2021. PMID: 34445639 Free PMC article. Review.
-
Small non-coding RNAs-based bone regulation and targeting therapeutic strategies.Mol Cell Endocrinol. 2017 Nov 15;456:16-35. doi: 10.1016/j.mce.2016.11.018. Epub 2016 Nov 23. Mol Cell Endocrinol. 2017. PMID: 27888003 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
